Investing in the Future of Rare Disease Therapies
A Unique Opportunity in Drug Repurposing
Fortuity Pharma offers a unique public benefit corporation investment opportunity by focusing on repurposing drugs like amlexanox for rare genetic disorders. By leveraging the safety and known efficacy of existing drugs, we are able to accelerate development timelines and reduce cost and risk, making us an attractive prospect for venture and philanthropic investors who want to make a difference for patients, and see a return of capital and potential financial upside.
For Healthcare and Community Foundations, Fortuity Pharma’s public benefit corporation status allows for rare disease community impact and potential return of capital to the Foundation if made as a Program-Related Investment (PRI).
Why Invest in Fortuity Pharma?
The Fortuity Pharma team believes clinicians are key partners in bringing novel therapies to the rare disease community. Our lead drug, amlexanox, has the potential to treat a variety of genetic conditions, and we need forward-thinking clinicians to help us evaluate its real-world impact through clinical trials, off-label use, and compassionate access programs.
Proven Leadership: Led by Dr. Bruce Bloom and others experts in drug repurposing, our team has a track record of successfully bringing repurposed therapies to those in need in the rare disease community.
Orphan Drug Potential: Amlexanox has the potential to qualify for Orphan Drug Designation, offering regulatory and market exclusivity benefits for up to seven years.
Scalable Impact: While we focus on rare genetic disorders, the mechanisms of action we are exploring have the potential to apply to a broad range of conditions, increasing the scope and impact of our therapies. There are also several other fortuitous and positive off-target impacts of amlexanox in obesity and cancer.
Strong Partnerships: Fortuity Pharma is proud to partner with Bright Path Labs, On Demand Pharmaceuticals, COMBINEDBrain, the WWOX Foundation & more.
Amlexanox is Cheap & Easy to Manufacture: Through our partnerships with established drug manufacturers, we have first-hand experience in quickly and inexpensively producing clinical-grade amlexanox.
Join Us in Making a Difference
We invite forward-thinking investors who share our passion for innovation and healthcare equity to partner with us. Together, we can deliver affordable, effective therapies to those affected by rare disease and create a model for ourselves and others to follow. For more information on investment opportunities, contact us.
LATEST NEWS & INSIGHTS
February 3, 2025
November 29, 2024